New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:14 EDTMTZ, ARIA, VTR, Z, NPSP, PBYI, OMER, HCT, BRCM, CYTK, PCYC, PL, SHPGOn The Fly: Pre-market Movers
HIGHER: NPS Pharmaceuticals (NPSP), up 21% after the Times of London reported that Shire (SHPG) secured a $5B credit facility led by Citigroup (C) for a takeover offer for the company... Broadcom (BRCM), up 15% after saying it will explore strategic alternatives for cellular baseband business, backing Q2 revenue expectations... Protective Life (PL) rises 17% after Dai-ichi Life Insurance reported to be in talks to buy the company... American Realty Capital (HCT) up 10% after Ventas (VTR) agreed to acquire the company for $2.6B in stock and cash. Ventas shares down 1.8% in pre-market trade following the deal announcement... Conn's (CONN), up 10% after reporting better than expected Q1 earnings results... ARIAD (ARIA), up 13.5% after FDA lifts partial clinical hold on Iclusig study. LOWER: MasTec (MTZ), down 13% after lowering its Q2 EPS view... Puma Biotechnology (PBYI), down 16% after presentation of PB272 Phase II data... Cytokinetics falls 8.8% after announcing further results from BENEFIT-ALS trial... Zillow (Z), down 4% after shares downgraded at Pacific Crest and at RBC Capital.
News For NPSP;SHPG;BRCM;Z;PL;HCT;VTR;PCYC;OMER;ARIA;CYTK;PBYI;MTZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 16, 2015
15:02 EDTZZillow Group to give MLS partners free public record data
Zillow Group announced it will begin offering its industry partners access to free public record data with broad usage rights, through a new program, Zillow Group Data Connect. In addition to public record data, ZGDC will offer MLSs the opportunity to receive, and share with members, dynamic, frequently-updated data from Zillow, such as the Zestimate and user-contributed data, like updates about renovations. Zillow Group's new program will allow partner MLSs to access information about properties, including mortgage information, tax rate, physical attributes, and mailing addresses, in addition to proprietary Zillow data. ZGDC is expected to be available in Q4.
April 15, 2015
09:11 EDTZZillow Group price target lowered to $121 from $145 at JMP Securities
Subscribe for More Information
07:35 EDTZZillow Group fundamentals should strengthen from here, says Canaccord
Canaccord noted Zillow held a conference call to update guidance following its Trulia acquisition. The firm said the company's outlook was negatively impacted by Trulia but that Zillow is enjoying strong performance. Canaccord expects synergies to kick in and sees the potential for ad pricing expansion as the company operates from a position of strength versus competitors. Canaccord maintained its Buy rating, but lowered its price target to $115 from $125 on Zillow Group shares.
06:35 EDTBRCMSamsung says Galaxy S6 demand much stronger than expected, Reuters reports
Subscribe for More Information
April 14, 2015
10:01 EDTZZillow Group dives in early trading, levels to watch
Subscribe for More Information
09:57 EDTZZillow resumes, down 9.2% to $85 after revenue guidance misses expectations
09:43 EDTZZillow Group trading to resume at 9:55 am EDT
Subscribe for More Information
09:25 EDTZZillow Group says FY15 is a 'transition year'
Subscribe for More Information
09:05 EDTZZillow Group sees FY15 revenue about $690M, consensus $752.97M
Subscribe for More Information
08:46 EDTPBYIPuma Biotechnology expands cohort in Phase II PB272 trial
Puma Biotechnology has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 as a single agent in patients with solid tumors who have an activating HER2 mutation. The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation. The Phase II basket trial, which was initiated in October 2013, is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating (driver) ERBB mutations, including epidermal growth factor receptor, HER2 and HER3. The cohorts (baskets) included in the study are (1) bladder/urinary tract cancer; (2) breast cancer; (3) colorectal cancer; (4) endometrial cancer; (5) gastric/esophageal cancer; (6) ovarian cancer; (7) all other solid tumors with a HER2 mutation; (8) EGFR mutated and/or amplified primary brain cancer; and (9) solid tumors with a HER3 mutation. The non-small cell lung cancer patients initially entered the study in the “other solid tumors with a HER2 mutation” basket and due to the preliminary activity seen in the trial the Company has expanded the basket, as per the protocol for the trial. The expanded HER2 mutant NSCLC basket will now enroll a total of 18 patients.
07:44 EDTZZillow Group April volatility low into call to discuss Trulia, FY15 outlook
Subscribe for More Information
07:08 EDTOMEROmeros' OMS721 receives European approval for compassionate use
Subscribe for More Information
April 13, 2015
19:18 EDTZOn The Fly: After Hours Movers
Subscribe for More Information
18:22 EDTZZillow Group to host conference call
Conference call to discuss acquisition of Trulia and provide an operational update will be held on April 14 at 9 am. Webcast Link
17:10 EDTZZillow Group hosting conference call April 14 to discuss Trulia, FY15 outlook
Subscribe for More Information
14:20 EDTARIANHS Scotland accepts ARIAD's Iclusig for use
Subscribe for More Information
14:07 EDTPCYCEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:04 EDTBRCMBroadcom calls active on renewed takeover chatter
Subscribe for More Information
09:52 EDTBRCMRumor: Broadcom strength attributed to renewed takeover speculation
Subscribe for More Information
07:20 EDTSHPGShire price target raised to $288 from $267 at JPMorgan
JPMorgan raised its price target for Shire to $288 after lifting its estimates for Lifitegrast in dry eye following the FDA's Priority Review designation. The firm believes the FDA is very likely to approve the application in October of this year, without waiting for the third Phase III study late 2015. It upped its 2020 Lifitegrast forecasts by $600M to $900M and reiterates an Overweight rating on Shire.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use